4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD
FDMT•Phase 3 dose selection
3E10 vg/eye was selected as the Phase 3 dose. The trial enrolled 45 patients across two dose levels.
Treatment-burden reduction and safety
The overall cohort showed a 78% treatment-burden reduction; the recently diagnosed subgroup showed an 87% reduction versus 12 projected aflibercept injections over 2 years.
The safety profile stayed stable; 2.8% mild intraocular inflammation was reported within 28 weeks, with no new inflammation reported beyond 28 weeks and up to 4+ years of follow-up.
Positive 2-year Phase 2b PRISM results
4D Molecular Therapeutics reported positive 2-year Phase 2b PRISM data for wet AMD gene therapy 4D-150, supporting its Phase 3 program.
A single intravitreal dose maintained visual acuity and retinal anatomy through 2 years, with a durable reduction in supplemental anti-VEGF injections.
